# Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

> **NCT00062504** · PHASE2 · TERMINATED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Anaplastic Oligodendroglioma
- Anaplastic Mixed Oligoastrocytoma

## Interventions

- **DRUG:** Talampanel

## Key facts

- **NCT ID:** NCT00062504
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-07
- **Primary completion:** 2006-01
- **Final completion:** 2006-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2011-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00062504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00062504, "Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00062504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*